Interactive Session:
22. Case-Based Problems in Vaccines: Beyond the Guidelines
Thursday, October 4, 2018: 8:45 AM-10:00 AM
Room: N 25

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • examine the current vaccine guidelines
  • differentiate public health vaccine decisions versus personal health
  • formulate vaccine decisions in unusual cases

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Medical students and residents, Members-in-training, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Adult ID, Epidemiology and Infection Control, Pediatric ID

Interactive Moderators:  H. Keipp Talbot, MD, MPH, Vanderbilt University Medical Center and Andrew Pavia, MD, FIDSA, FSHEA, FPIDS, University of Utah School of Medicine

Interactive Panelists:  Nicola P. Klein, MD, PhD, Kaiser Permanente Vaccine Study Center , C. Mary Healy, MD, FIDSA, Baylor College of Medicine and Kathryn Edwards, MD, FIDSA, Vanderbilt University School of Medicine

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 application-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-193-L04-P


H. K. Talbot, Sanofi Pasteur: Investigator , Research grant . Gilead: Investigator , Research grant . MedImmune: Investigator , Research grant . Vaxinnate: Safety Board , none . Seqirus: Safety Board , none .

A. Pavia, None

N. P. Klein, Sanofi Pasteur: Investigator , Research grant . Merck: Investigator , Research grant . GSK: Investigator , Research grant . Pfizer: Investigator , Research support . Protein Science: Investigator , Research grant . MedImmune: Investigator , Research grant . Dynavax: Research Contractor , Grant recipient .

C. M. Healy, None

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.